Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06638671 · ClinicalTrials.gov registry record · Phase 4
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity
A Phase 4 study of Exercise Capacity and Metformin, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06638671: Recruiting Phase 4 study of Exercise Capacity and Metformin, sponsored by University of Virginia.
NCT06638671 is a Phase 4 study of Exercise Capacity and Metformin that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06638671, a Phase 4 study of Exercise Capacity and Metformin, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity. The main question this study looks to answer is: • Does metformin alter exercise capacity? Participants will: * Complete 5 exercise tests on a stationary bike. * Undergo a body composition test. * Take metformin and placebo. * Complete food and symptom logs. The researchers hypothesize that: • Metformin will reduce aerobic capacity.
Primary Outcome
Exercise capacity will be measured by absolute and relative VO2peak
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin Hydrochloride
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 4 |
What NCT06638671 shows while recruiting
NCT06638671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Exercise Capacity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06638671 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06638671 about?
NCT06638671 is a clinical study titled "Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity". Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity...
What is the current status of trial NCT06638671?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-01-31. Estimated completion is 2026-04-01.
What conditions does trial NCT06638671 study?
This clinical trial studies the following conditions: Exercise Capacity, Metformin.
What interventions are being tested in trial NCT06638671?
The interventions under investigation include: Placebo (DRUG), Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06638671?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06638671 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exercise Capacity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06638671's enrollment target sits among peer trials
20 1753rd of 2000 higher than 168 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI